Skip to main content
Erschienen in: European Radiology 9/2013

01.09.2013 | Interventional

Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up

verfasst von: Joao Martins Pisco, Hugo Rio Tinto, Luís Campos Pinheiro, Tiago Bilhim, Marisa Duarte, Lúcia Fernandes, José Pereira, António G. Oliveira

Erschienen in: European Radiology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the short- and medium-term results of prostatic arterial embolisation (PAE) for benign prostatic hyperplasia (BPH).

Methods

This was a prospective non-randomised study including 255 patients diagnosed with BPH and moderate to severe lower urinary tract symptoms after failure of medical treatment for at least 6 months. The patients underwent PAE between March 2009 and April 2012. Technical success is when selective prostatic arterial embolisation is completed in at least one pelvic side. Clinical success was defined as improving symptoms and quality of life. Evaluation was performed before PAE and at 1, 3, 6 and every 6 months thereafter with the International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function (IIEF), uroflowmetry, prostatic specific antigen (PSA) and volume. Non-spherical polyvinyl alcohol particles were used.

Results

PAE was technically successful in 250 patients (97.9 %). Mean follow-up, in 238 patients, was 10 months (range 1–36). Cumulative rates of clinical success were 81.9 %, 80.7 %, 77.9 %, 75.2 %, 72.0 %, 72.0 %, 72.0 % and 72.0 % at 1, 3, 6, 12, 18, 24, 30 and 36 months, respectively. There was one major complication.

Conclusions

PAE is a procedure with good results for BPH patients with moderate to severe LUTS after failure of medical therapy.

Key Points

Prostatic artery embolisation offers minimally invasive therapy for benign prostatic hyperplasia.
Prostatic artery embolisation is a challenging procedure because of vascular anatomical variations.
PAE is a promising new technique that has shown good results.
Literatur
1.
Zurück zum Zitat Levy A, Samraj GP (2007) Benign prostatic hyperplasia: when to ‘watch and wait’, when and how to treat. Cleve Clin J Med 74:S15–S20PubMedCrossRef Levy A, Samraj GP (2007) Benign prostatic hyperplasia: when to ‘watch and wait’, when and how to treat. Cleve Clin J Med 74:S15–S20PubMedCrossRef
2.
Zurück zum Zitat Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469–471PubMedCrossRef Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469–471PubMedCrossRef
3.
Zurück zum Zitat Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schäfers RF, Goepel M (1998) Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160:784–791PubMedCrossRef Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schäfers RF, Goepel M (1998) Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160:784–791PubMedCrossRef
4.
Zurück zum Zitat McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563PubMedCrossRef McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563PubMedCrossRef
5.
Zurück zum Zitat Varkarakis J, Bartsch G, Horninger W (2004) Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up. Prostate 58:248–251PubMedCrossRef Varkarakis J, Bartsch G, Horninger W (2004) Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up. Prostate 58:248–251PubMedCrossRef
6.
Zurück zum Zitat Roehrborn CG, Rosen RC (2008) Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging 3:511–524PubMed Roehrborn CG, Rosen RC (2008) Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging 3:511–524PubMed
7.
Zurück zum Zitat Burnett AL, Wein AJ (2006) Benign prostatic hyperplasia in primary care: what you need to know. J Urol 175:S19–S24PubMedCrossRef Burnett AL, Wein AJ (2006) Benign prostatic hyperplasia in primary care: what you need to know. J Urol 175:S19–S24PubMedCrossRef
8.
Zurück zum Zitat Baazeem A, Elhilali MM (2008) Surgical management of benign prostatic hyperplasia: current evidence. Nat Clin Pract Urol 5:540–549PubMedCrossRef Baazeem A, Elhilali MM (2008) Surgical management of benign prostatic hyperplasia: current evidence. Nat Clin Pract Urol 5:540–549PubMedCrossRef
9.
Zurück zum Zitat Reich O, Gratzke C, Bachman A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180:246–249PubMedCrossRef Reich O, Gratzke C, Bachman A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180:246–249PubMedCrossRef
10.
Zurück zum Zitat Madersbacher S, Marberger M (1999) Is transurethral resection of the prostate still justified? BJU Int 83:227–237PubMedCrossRef Madersbacher S, Marberger M (1999) Is transurethral resection of the prostate still justified? BJU Int 83:227–237PubMedCrossRef
11.
Zurück zum Zitat DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS (2000) Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol 11:767–770PubMedCrossRef DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS (2000) Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol 11:767–770PubMedCrossRef
12.
Zurück zum Zitat Carnevale FC, Antunes AA, da Motta Leal Filho JM et al (2010) Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol 33:355–361PubMedCrossRef Carnevale FC, Antunes AA, da Motta Leal Filho JM et al (2010) Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol 33:355–361PubMedCrossRef
13.
Zurück zum Zitat Pisco JM, Pinheiro LC, Bilhim T, Duarte M, Mendes JR, Oliveira AG (2011) Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol 22:11–19PubMedCrossRef Pisco JM, Pinheiro LC, Bilhim T, Duarte M, Mendes JR, Oliveira AG (2011) Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol 22:11–19PubMedCrossRef
14.
Zurück zum Zitat Sun F, Sánchez FM, Crisóstomo V et al (2008) Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment—preliminary study in pigs. Radiology 246:783–789PubMedCrossRef Sun F, Sánchez FM, Crisóstomo V et al (2008) Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment—preliminary study in pigs. Radiology 246:783–789PubMedCrossRef
15.
Zurück zum Zitat Jeon GS, Won JH, Lee BM et al (2009) The effect of transarterial prostate embolization in hormone-induced benign prostatic hyperplasia in dogs: a pilot study. J Vasc Interv Radiol 20:384–390PubMedCrossRef Jeon GS, Won JH, Lee BM et al (2009) The effect of transarterial prostate embolization in hormone-induced benign prostatic hyperplasia in dogs: a pilot study. J Vasc Interv Radiol 20:384–390PubMedCrossRef
16.
Zurück zum Zitat Mauro MA (2008) Can hyperplastic prostate follow uterine fibroids and be managed with transcatheter arterial embolization? Radiology 246:657–658PubMedCrossRef Mauro MA (2008) Can hyperplastic prostate follow uterine fibroids and be managed with transcatheter arterial embolization? Radiology 246:657–658PubMedCrossRef
17.
Zurück zum Zitat Bilhim T, Casal D, Furtado A, Pais D, O’Neill JE, Pisco JM (2011) Branching patterns of the male internal iliac artery: imaging findings. Surg Radiol Anat 33:151–159PubMedCrossRef Bilhim T, Casal D, Furtado A, Pais D, O’Neill JE, Pisco JM (2011) Branching patterns of the male internal iliac artery: imaging findings. Surg Radiol Anat 33:151–159PubMedCrossRef
18.
Zurück zum Zitat Bilhim T, Pisco JM, Furtado A et al (2011) Prostatic arterial supply: demonstration by multirow detector angio CT and catheter angiography. Eur Radiol 21:1119–1126PubMedCrossRef Bilhim T, Pisco JM, Furtado A et al (2011) Prostatic arterial supply: demonstration by multirow detector angio CT and catheter angiography. Eur Radiol 21:1119–1126PubMedCrossRef
19.
Zurück zum Zitat Sapoval M, Daroles J, Rio Tinto H et al (2012) C-arm cone-beam CT in BPH: techniques and considerations for the safe treatment of benign prostatic hyperplasia. Endovascular Today April:61–63 Sapoval M, Daroles J, Rio Tinto H et al (2012) C-arm cone-beam CT in BPH: techniques and considerations for the safe treatment of benign prostatic hyperplasia. Endovascular Today April:61–63
Metadaten
Titel
Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up
verfasst von
Joao Martins Pisco
Hugo Rio Tinto
Luís Campos Pinheiro
Tiago Bilhim
Marisa Duarte
Lúcia Fernandes
José Pereira
António G. Oliveira
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 9/2013
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-012-2714-9

Weitere Artikel der Ausgabe 9/2013

European Radiology 9/2013 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.